1,2 College of Pharmacy, Madurai Medical College, Madurai-20, Tamil Nadu, India
3 KMCH College of Pharmacy, Coimbatore-641048, Tamil Nadu, India
4,5 Sri Ramakrishna Institute of Paramedical Sciences, College of Pharmacy, Coimbatore-641044, Tamil Nadu, India
Artificial Intelligence (AI) refers to the simulation of human intelligence processes by computer systems. AI encompasses machine learning, natural language processing, deep learning, and other advanced computational approaches. Clinical drug development is the multi-phase process of bringing a new pharmaceutical compound from laboratory discovery through human testing to market approval, involving rigorous assessments of safety, efficacy, and pharmacokinetics across Phases I to IV. This review explores applications of AI tools across all critical steps of clinical drug development that includes selection of investigational sites, participant recruitment, patient selection and stratification, treatment optimization, clinical trial data collection, trial management, report generation, pharmacovigilance, and regulatory submissions. AI aids in identifying high-performing sites, predicting patient eligibility, tailoring treatment arms, ensuring high-quality data capture, and detecting safety signals in real time. Despite challenges such as data bias and regulatory hurdles, AI holds transformative potential. This article presents a step-by-step analysis of AI’s role in clinical research, highlighting current tools, advantages over conventional methods.
The integration of Artificial Intelligence (AI) into healthcare, and particularly into clinical drug development, represents a paradigm shift in how novel therapeutics are discovered, evaluated, and brought to market. AI, broadly defined as the capability of machines to perform tasks that typically require human intelligence, encompasses a range of subfields, with Machine Learning (ML) being one of the most impactful. ML algorithms, which enable systems to learn patterns from large datasets and improve performance over time, have shown significant promise in addressing longstanding challenges in pharmaceutical research and development (R&D) [1].
Historically, drug development has been characterized by high attrition rates, prolonged timelines (often exceeding 10–15 years), and substantial financial investment, with costs frequently surpassing USD 2 billion per approved compound. The conventional model, heavily reliant on hypothesis-driven research and labour-intensive trial-and-error methodologies, is increasingly being augmented—and in some cases replaced—by data-driven approaches enabled by AI technologies [2].
A growing ecosystem of AI tools and platforms now supports various stages of the drug development lifecycle. Applications range from target identification and validation, compound screening, and biomarker discovery, to clinical trial optimization, patient stratification, and real-time monitoring of trial data. Notable platforms include IBM Watson for Drug Discovery, DeepMind’s AlphaFold for protein structure prediction, Benevolent AI, and others that utilize natural language processing (NLP), neural networks, and predictive analytics.
The benefits of AI integration are multifaceted. Compared to traditional methodologies, AI offers enhanced efficiency, reduced cost, shortened development timelines, and improved decision-making accuracy. Moreover, the ability of AI systems to integrate and analyse diverse data sources—ranging from omics data and Electronic Health Records (EHRs) to Real-World Evidence (RWE)—is facilitating a more personalized, patient-centric approach to drug development [3].
A comparative look at past and present practices underscores the magnitude of this transformation. Where manual curation and limited computational resources once constrained innovation, today’s AI-enabled platforms offer high-throughput, scalable, and predictive solutions that are redefining industry benchmarks.
This review aims to critically examine the current landscape of AI in clinical drug development, highlighting key applications, emerging tools, and future directions, while also addressing the challenges and limitations that must be considered for broader implementation.
APPROACHES AND UTILITY OF AI
Artificial Intelligence (AI) encompasses a wide range of computational techniques designed to mimic cognitive functions such as learning, reasoning, and problem-solving. In the context of clinical drug development, AI methodologies are primarily driven by Machine Learning (ML), Deep Learning (DL), Natural Language Processing (NLP), and predictive modelling, each offering unique utilities across various phases of the drug development lifecycle [4-6].
Machine learning and deep learning
Machine Learning algorithms, particularly supervised, unsupervised, and reinforcement learning, are extensively applied for analysing high-dimensional biomedical datasets. For example, supervised learning models are used to predict drug efficacy or adverse effects based on clinical and molecular features, while unsupervised models are deployed for clustering patients into subgroups based on response biomarkers.
Deep Learning, a subset of ML, uses multi-layered neural networks to uncover complex patterns in unstructured data such as medical imaging, genomics, and electronic health records (EHRs). Notable implementations include convolutional neural networks (CNNs) for analysing histopathological slides and recurrent neural networks (RNNs) for sequential clinical data analysis.
Natural language processing (NLP)
NLP enables the extraction of structured insights from unstructured text data, including scientific literature, clinical trial protocols, and patient records. NLP tools like IBM Watson and BioBERT are employed for drug repurposing, identifying off-target effects, and summarizing preclinical evidence from published studies. This significantly reduces the time and manual effort required in literature curation and knowledge synthesis.
Predictive analytics and modelling
Predictive modelling combines statistical algorithms with machine learning techniques to forecast clinical outcomes, optimize dosing regimens, and stratify patients. AI models have been used to simulate virtual patient cohorts, enabling in silico trials that can predict likely responses to investigational drugs. Such tools are valuable in early-phase development, where minimizing risk is crucial.
Generative AI and drug design
Emerging tools such as Generative Adversarial Networks (GANs) and transformer-based models (e.g., AlphaFold2) are being utilized for de novo drug design and protein structure prediction. These models accelerate hit-to-lead identification and assist medicinal chemists by generating novel compound structures with predicted binding affinity and pharmacokinetic profiles.
Integration with clinical trials
AI is increasingly integrated into clinical trial design and management. Tools that analyze real-world data (RWD) and EHRs enable site selection, patient recruitment, and adaptive trial designs. For instance, predictive enrolment algorithms improve efficiency by identifying eligible patients more accurately, thereby reducing trial delays and dropout rates.
Table 1: Integration of AI into Clinical Drug Development Stages
|
Phase |
AI Utility |
|
Target Identification |
Mining omics data, literature mining |
|
Preclinical Testing |
Toxicity prediction, compound screening |
|
Clinical Trials |
Patient stratification, adverse event prediction, trial simulation |
|
Post-Marketing Surveillance |
Pharmacovigilance, signal detection from RWE {Real world evidence} [5-6] |
Figure. 1. Role of Generative AI in modern clinical trials
SELECTION OF INVESTIGATOR SITES
The selection of investigator sites is a critical component in the planning and execution of clinical trials, significantly impacting recruitment rates, data quality, regulatory compliance, and overall trial efficiency. With the integration of Artificial Intelligence (AI) and Machine Learning (ML), site selection has become increasingly data-driven, objective, and predictive. AI algorithms can analyse a vast array of data sources—including electronic health records (EHRs), claims databases, real-world evidence (RWE), and prior trial performance metrics—to identify optimal sites with a high likelihood of meeting recruitment targets, maintaining compliance, and delivering high-quality data [7-9].
Table 2: List of AI Tools in selection of Investigator sites
|
AI Application |
Key Tools/Platforms |
Functionality |
Benefits |
|
Predictive Site Performance |
IQVIA Site ID, Medidata Clinical Cloud |
Analyses historical recruitment and performance data |
Identifies high-performing sites; improves trial timelines |
|
EHR and RWD Mining |
TriNetX, Deep 6 AI |
Extracts patient population data and eligibility |
Optimizes site location based on patient availability |
|
Natural Language Processing (NLP) |
IBM Watson, Linguamatics |
Processes feasibility forms, investigator CVs |
Automates data extraction; enhances site evaluation |
|
Geospatial Analysis |
SAS Visual Analytics, Tableau AI |
Maps epidemiological and demographic data |
Selects sites with access to relevant patient populations |
|
Performance Benchmarking |
Oracle Health Sciences, Veeva Systems |
Compares sites against industry benchmarks |
Reduces operational risks; supports evidence-based decisions [9-11] |
ENROLLMENT OF PARTICIPANTS
Participant enrollment is vital to the success of clinical trials across all phases—ranging from early-phase safety studies to large-scale Phase III efficacy trials. Each phase presents unique challenges in identifying and recruiting eligible subjects. Traditional methods often result in delays and under-enrolment. Artificial Intelligence (AI) enhances the recruitment process by leveraging real-world data, electronic health records, and predictive analytics to identify suitable participants efficiently. AI tools can also optimize protocol criteria and forecast enrolment rates, reducing recruitment timelines and improving trial success. This data-driven approach supports faster, more inclusive, and cost-effective drug development at every phase [12-13].
Table 3: List of AI Tools in Enrolment of Participants
|
Clinical Trial Phase |
AI Application |
Key Tools/Examples |
Outcomes/Benefits |
|
Phase I |
Screening healthy volunteers using eligibility criteria |
Deep 6 AI, IBM Watson Health |
Faster identification of suitable subjects; reduced time to first dose |
|
Phase II |
Matching patients with specific disease characteristics |
Trial Matching Algorithms, EHR mining tools |
Improved patient targeting; better trial population fit |
|
Phase III |
Predictive modelling for large-scale recruitment |
TriNetX, IQVIA Patient Recruitment Platform |
Reduced recruitment timelines; optimized site-level planning |
|
Phase IV (Post-marketing) |
Real-world data analysis for long-term follow-up |
Flatiron Health, Aetion |
Enhanced post-marketing surveillance; better patient retention tracking [14] |
Figure. 2. Role of AI in Participant Selection
SELECTION AND STRATIFICATION OF TRIAL PARTICIPANTS
Artificial Intelligence (AI) enhances participant selection by integrating multi-dimensional data—including genomics, biomarkers, clinical history, and real-world evidence—to identify eligible candidates more precisely. Stratification algorithms further categorize patients into homogeneous subgroups based on disease phenotypes, genetic profiles, or risk factors. This targeted approach not only improves statistical power but also enables personalized treatment evaluation, optimizing therapeutic outcomes and minimizing adverse events [15-17].
Table 4: List of AI Tools in Selection and stratification of trial participants
|
Application |
AI Tools/ Platforms |
Description |
Benefits |
|
Participant Selection |
Deep 6 AI, IBM Watson Health |
Mining EHRs and clinical data to identify eligible patients |
Faster, accurate patient identification |
|
Genomic and Biomarker Stratification |
Tempus, Foundation Medicine |
Integrates genomic and biomarker data for subgrouping |
Enables precision medicine and targeted therapies |
|
Risk-based Stratification |
SAS, R Shiny AI models |
Uses predictive analytics on clinical and demographic data |
Improves safety monitoring and efficacy analysis |
|
Adaptive Trial Design Support |
Medidata, Oracle Health Sciences |
AI-driven dynamic inclusion/exclusion criteria |
Facilitates real-time trial modifications |
Figure. 3. Role of AI in Clinical Trials
STUDY TREATMENT
The administration and monitoring of study treatment in clinical trials are crucial for assessing drug safety and efficacy. Traditional approaches often rely on fixed dosing regimens and standardized protocols, which may not account for inter-patient variability. Artificial Intelligence (AI) offers innovative solutions by enabling personalized treatment strategies through predictive analytics and real-time monitoring.
AI-driven models can optimize dosing by analysing pharmacokinetic and pharmacodynamic data, patient-specific characteristics, and treatment response patterns. Additionally, AI-powered digital tools facilitate adherence monitoring and adverse event detection, enhancing patient safety. Such dynamic and adaptive treatment management improves trial outcomes and supports precision medicine initiatives in drug development [18-20].
Table 5: List of AI Tools in Study Treatment
|
Application |
AI Tools/ Platforms |
Description |
Benefits |
|
Dosing Optimization |
IBM Watson for Clinical Trial Optimization, Deep Dose |
Uses PK/PD modelling and patient data to personalize dosing |
Improves efficacy, reduces adverse effects |
|
Adherence Monitoring |
Medisafe, AI Cure |
Digital platforms leveraging AI to track medication adherence |
Enhances patient compliance, supports remote monitoring |
|
Adverse Event Prediction |
Tempus, Safewatch |
Predictive models analysing real-time patient data for early detection of side effects |
Improves patient safety and trial management |
|
Treatment Response Prediction |
Flatiron Health, BioXcel |
AI models that analyse biomarkers and clinical data to forecast treatment outcomes |
Facilitates adaptive treatment adjustments |
RETENTION OF PARTICIPANTS
Artificial Intelligence (AI) provides innovative solutions by analysing behavioural, demographic, and engagement data to predict participants at risk of withdrawal. AI-powered platforms enable personalized communication, timely reminders, and adaptive interventions tailored to individual needs. This proactive approach improves participant engagement, reduces dropout rates, and ultimately enhances the quality and success rate of clinical trials [21-23].
Table 6: List of AI Tools in retention of participants
|
Application |
AI Tools/ Platforms |
Description |
Benefits |
|
Dropout Risk Prediction |
Evidation Health, Medidata |
Uses predictive analytics on engagement and behavioural data to identify at-risk participants |
Enables early interventions to reduce dropout |
|
Personalized Communication |
Trial bee, Science 37 |
AI-driven platforms for tailored messaging and reminders |
Improves participant engagement and adherence |
|
Remote Monitoring & Support |
AI Cure, Veeva Systems |
AI-enabled digital health tools for real-time monitoring |
Enhances support, reduces participant burden |
|
Adaptive Retention Strategies |
Oracle Health Sciences, Medidata |
Dynamically adjusts retention approaches based on participant feedback and data |
Increases trial completion rates |
CLINICAL TRIAL DATA COLLECTION, MANAGEMENT, REPORT
Clinical trial data collection is the systematic gathering of patient information, including demographics, treatment outcomes, and adverse events, using electronic data capture (EDC) systems. AI-powered tools enhance data accuracy by automating entry and identifying anomalies in real-time. Efficient data management involves integrating, cleaning, and securing vast datasets to ensure compliance with regulatory standards. Machine learning algorithms assist in monitoring data quality and predicting data trends. Reporting utilizes AI-driven analytics to generate comprehensive insights, facilitating faster decision-making and regulatory submissions. Together, these technologies streamline workflows, reduce errors, and improve trial transparency, accelerating drug development and ensuring robust evidence generation [24-27].
Table 7: List of AI Tools in clinical trial data collection, management and report
|
Application |
AI Tools/ Platforms |
Functionality |
Benefits |
|
Data Collection & Entry |
Medidata Rave, Castor EDC |
Electronic data capture with AI-driven error detection |
Increases data accuracy; reduces manual errors |
|
Data Management |
Oracle Health Sciences, SAS |
Integration, cleaning, and secure storage of trial data |
Ensures regulatory compliance; enhances data integrity |
|
Data Monitoring |
CluePoints, TrialScope |
AI algorithms detect anomalies and trends in real-time |
Improves data quality; reduces monitoring costs |
|
Reporting & Analytics |
IBM Watson Health, Tableau AI |
Generates analytical reports and visualizations |
Speeds regulatory submission; facilitates informed decisions |
PHARMACOVIGILANCE
Artificial Intelligence (AI) is revolutionizing pharmacovigilance by automating the detection, assessment, and reporting of adverse drug reactions (ADRs). Machine learning algorithms analyse large volumes of structured and unstructured data from sources like electronic health records, social media, and spontaneous reporting systems. Natural Language Processing (NLP) helps extract relevant safety information from clinical notes and literature. AI enhances signal detection by identifying patterns and predicting potential safety risks earlier than traditional methods. This accelerates regulatory reporting and improves patient safety. Furthermore, AI-driven automation reduces manual workload, minimizes errors, and enables continuous monitoring, making pharmacovigilance more proactive and efficient [28-30].
Table 8: List of AI Tools in Pharmacovigilance
|
Application |
AI Tools/Platforms |
Description |
Benefits |
|
Adverse Event Detection |
IBM Watson for Drug Safety, ArisGlobal |
Uses ML and NLP to extract and analyse safety reports |
Faster and more accurate identification of ADRs |
|
Signal Detection |
Oracle Argus Safety, VigiBase AI |
Predictive analytics to identify emerging safets signals |
Early warning of potential drug safety issues |
|
Case Processing Automation |
Saama Life Science Analytics, EXTEDO |
Automates case intake, coding, and narrative writing |
Reduces manual workload; improves processing speed |
|
Social Media Monitoring |
MedWatcher, Socialgist |
Monitors patient conversations for safety signals |
Captures real-world safety data beyond traditional sources |
AI IN REGULATORY SUBMISSIONS
Artificial Intelligence (AI) is transforming regulatory submissions by streamlining the compilation, review, and analysis of complex datasets required for Investigational New Drug (IND), Abbreviated New Drug Application (ANDA), and New Drug Application (NDA) filings. AI-powered tools automate document generation, cross-reference validation, and compliance checks, significantly reducing manual effort and errors. Natural Language Processing (NLP) assists in extracting relevant information from vast scientific literature and regulatory guidelines, ensuring up-to-date submissions. Predictive analytics enable forecasting of regulatory review outcomes and timelines, facilitating proactive risk management. Overall, AI enhances submission quality, accelerates approval processes, and supports regulatory compliance in an increasingly data-intensive environment [31-32].
Table 9: List of AI Tools in Regulatory submissions
|
Application |
AI Tools/Platforms |
Functionality |
Benefits |
|
Document Automation |
Veeva Vault, Cognizant AI |
Automates generation, formatting, and cross-checking of regulatory documents |
Reduces manual errors; accelerates submission preparation |
|
NLP for Literature & Guideline Mining |
IBM Watson, LexisNexis AI |
Extracts and organizes relevant regulatory and scientific data |
Ensures compliance with current guidelines; improves accuracy |
|
Predictive Analytics for Review Outcomes |
Cortellis Regulatory Intelligence, Pharma.AI |
Forecasts regulatory review timelines and identifies potential issues |
Supports proactive planning and risk mitigation |
|
Data Integration & Validation |
Oracle Health Sciences, Medidata |
Integrates multiple data sources ensuring consistency and compliance |
Enhances data integrity and audit readiness |
Figure. 4. Role of AI in Preclinical Drug Development
Table 10: Comparison of Conventional and AI Methods in Clinical Drug Development
|
Topic |
Conventional Method |
AI Method |
|
Approaches and Benefits of AI |
Traditional drug development relies heavily on manual data analysis and expert-driven decisions. Rule-based systems offer limited adaptability and scalability. AI incorporates advanced machine learning, deep learning, and natural language processing techniques. These enable systems to learn from large, complex datasets and continuously improve. This results in more efficient data interpretation and better decision support across clinical development stages. |
Machine learning algorithms and deep learning models analyze diverse data types, including genomic and real-world data. AI tools automate pattern recognition and predictive modeling. Natural language processing extracts insights from unstructured texts like clinical notes. These methods improve the speed and accuracy of analyses, helping to uncover hidden patterns and optimize trial design and execution. |
|
Selection of Investigator Sites |
Site selection has traditionally been based on historical site performance, investigator reputation, and manual feasibility assessments. This process is time-consuming and often lacks comprehensive patient population insights. Site feasibility forms and expert opinion dominate decision-making. Limited integration of real-world patient data and recruitment potential analysis often results in suboptimal site choices. |
AI-powered predictive analytics use electronic health records (EHR), clinical trial databases, and geospatial analysis to evaluate potential sites. Platforms mine real-world patient data to estimate recruitment feasibility and past site performance metrics. Natural language processing extracts data from feasibility questionnaires, and machine learning predicts site activation speed and enrollment capacity. |
|
Enrolment of Participants |
Enrolment relies on physician referrals, patient registries, and manual eligibility screening using paper or electronic case report forms. Patient matching to trials is often inefficient and slow. Recruitment bottlenecks can delay study start-up and extend timelines. Screening criteria may not be dynamically updated based on emerging data. This results in slow, costly recruitment with high screen failure rates. |
AI tools utilize real-world data and EHR mining to identify eligible patients rapidly. Predictive modelling forecasts recruitment rates and suggests optimized enrolment strategies. Adaptive algorithms dynamically adjust inclusion/exclusion criteria based on ongoing trial data. Digital platforms enable real-time matching of patients to appropriate studies. |
|
Selection and Stratification |
Stratification typically involves grouping patients based on basic demographics or limited biomarker data. This approach may not capture underlying disease heterogeneity or genetic variability. Often, stratification is static and does not adapt to evolving clinical or molecular insights. Personalized treatment approaches are limited, impacting trial sensitivity and outcome interpretation. |
AI integrates multi-omics data, biomarkers, clinical history, and real-world evidence to perform deep phenotyping and stratification. Machine learning algorithms create dynamic patient clusters reflecting biological and clinical variability. Adaptive stratification supports ongoing trial modifications based on interim data, optimizing subgroup analyses. |
|
Study Treatment |
Study treatments are generally administered with fixed dosing regimens determined by early-phase studies. Adherence monitoring is often manual, relying on patient self-report or pill counts. Adjustments during trials are limited and based on periodic assessments. This can lead to suboptimal dosing, safety issues, or lack of personalized treatment optimization. |
AI models incorporate pharmacokinetic/pharmacodynamic (PK/PD) data and patient-specific characteristics to optimize dosing regimens. Digital adherence tools use sensors and AI analytics to monitor real-time compliance. Predictive models forecast treatment response and adverse events, enabling personalized and adaptive treatment management throughout the trial. |
|
Retention of Participants |
Retention strategies include scheduled follow-ups, reminder calls, and occasional incentives. Dropout risk is often assessed reactively rather than proactively. Loss of participants leads to reduced statistical power and potential bias. Engagement efforts are generally one-size-fits-all, limiting effectiveness in diverse populations. |
AI analyses behavioural, demographic, and engagement data to predict dropout risks early. Personalized communication platforms use AI-driven messaging tailored to individual preferences. Remote monitoring and support tools provide continuous engagement and timely interventions. AI adapts retention strategies dynamically based on participant feedback and data. |
|
Data Collection & Management |
Data collection traditionally involves manual entry into case report forms and siloed databases. Data cleaning and validation are labour-intensive, delaying analyses. Compliance with regulatory standards requires extensive manual checks. Data integration from multiple sources is challenging, often resulting in fragmented datasets and quality issues. |
AI-enhanced electronic data capture (EDC) systems automate data entry with real-time error detection. Machine learning algorithms monitor data quality, identify anomalies, and support automated cleaning. Integrated platforms unify disparate data sources, ensuring consistency and regulatory compliance. AI assists in predictive data trend analysis and audit readiness. |
|
Pharmacovigilance |
Pharmacovigilance relies on manual reporting of adverse drug reactions (ADRs) through spontaneous reports and case processing. Signal detection is often retrospective and limited by data volume and variability. Processing case narratives and literature reviews is labour-intensive and time-consuming, delaying safety assessments. |
AI employs natural language processing (NLP) to extract safety information from unstructured data, including clinical notes and social media. Machine learning models detect safety signals and predict adverse event risks earlier. Automation accelerates case intake, coding, and narrative generation, enhancing pharmacovigilance efficiency and accuracy. |
|
Regulatory Submissions (IND, ANDA, NDA) |
Regulatory submissions are traditionally manual processes involving extensive document preparation, formatting, and compliance checks. Guideline interpretation requires expert review. Predicting review outcomes and timelines is challenging, complicating submission planning. |
AI automates document generation, cross-validation, and formatting, ensuring consistency and compliance. Natural language processing extracts relevant regulatory guidelines and scientific literature. Predictive analytics forecast review timelines and potential regulatory concerns, enabling proactive risk management. |
CONCLUSION
Artificial Intelligence is revolutionizing clinical drug development by enhancing efficiency, reducing costs, and accelerating timelines. From target identification and patient recruitment to trial monitoring and data analysis, AI enables deeper insights and smarter decision-making at every stage of the process. While challenges remain such as data quality, regulatory concerns, and ethical considerations the integration of AI holds tremendous potential to transform how new therapies are discovered and delivered. As the technology continues to evolve, a collaborative approach between researchers, clinicians, regulators, and AI experts will be crucial to unlocking its full impact and ensuring that drug development becomes faster, safer, and more patient-centered than ever before.
REFERENCES
Preethi. J, Punniyamoorthy. K, Rejina. C, Dharanikumar S, Prathiksha M, AI-Enabled Transformation in Clinical Drug Development: A Pathway from Innovation to Patient Care, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 10, 3039-3050. https://doi.org/10.5281/zenodo.17470496
0.5281/zenodo.17470496
